Regeneron is gearing up to jump into the highly lucrative obesity market with a Phase II trial for its muscle-conserving antibodies slated for the middle of 2024, the company revealed Friday during its fourth-quarter and full-year 2023 earnings presentation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,